Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics
SGMO Stock Summary
- Of note is the ratio of Sangamo Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 14.12% of US stocks have a lower such ratio.
- For SGMO, its debt to operating expenses ratio is greater than that reported by only 15.52% of US equities we're observing.
- SGMO's price/sales ratio is 14.2; that's higher than the P/S ratio of 86.63% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sangamo Therapeutics Inc are DTIL, SRRK, GLYC, CMRX, and ALPN.
- Visit SGMO's SEC page to see the company's official filings. To visit the company's web site, go to www.sangamo.com.
SGMO Stock Price Chart Interactive Chart >
SGMO Price/Volume Stats
|Current price||$11.85||52-week high||$19.43|
|Prev. close||$11.87||52-week low||$7.65|
|Day high||$12.17||Avg. volume||1,479,088|
|50-day MA||$12.04||Dividend yield||N/A|
|200-day MA||$11.99||Market Cap||1.70B|
Sangamo Therapeutics, Inc. (SGMO) Company Bio
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.
SGMO Latest News Stream
|Loading, please wait...|
SGMO Latest Social Stream
View Full SGMO Social Stream
Latest SGMO News From Around the Web
Below are the latest news stories about Sangamo Therapeutics Inc that investors may wish to consider to help them evaluate SGMO as an investment opportunity.
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study partnered with Sanofi. The Committee’s decision to grant Orphan Designation was based in part on early data from three patients that had 52 weeks, 13 weeks, and 29 days of follow-up, respectively.
reward paradigm comes into play.
Global Hemophilia Gene Therapy Market by Share, Vendors, Growth Rate, Analysis, Product Type, Revenue | Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics
Latest Research Study on Global Hemophilia Gene Therapy Market published by Research N Reports, offers a detailed overview of the factors influencing the global business scope. Hemophilia Gene Therapy Market research report shows the latest market insights with upcoming trends
mRNA Vaccines & Therapeutics Market Swot Analysis by key players CureVac, Translate Bio, BioNTech, Sangamo Therapeutics
Latest Market intelligence report released by HTF MI with title "Global mRNA Vaccines & Therapeutics Market Growth 2021-2026" is designed covering micro level of analysis by manufacturers and key business segments. The Global mRNA Vaccines & Therapeutics Market survey analysis
Wasatch Ultra Growth Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 23.2% for the quarter, underperforming its benchmark, the Russell 2,000 Growth Index which returned 29.6% in the same quarter. You should check out Wasatch’s top 5 stock picks for investors […]
SGMO Price Returns
Continue Researching SGMOWant to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:
Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch